Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606571 | 0.82 | ALDH1A1 (0.48) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7607878 | 0.81 | PDE5A (0.42) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7610675 | 0.81 | PDE5A (0.69) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7277566 | 0.80 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7280050 | 0.80 | PDE5A (0.84) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7610950 | 0.80 | PDE5A (0.41) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7608988 | 0.79 | PDE5A (0.66) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| Hydrochloric Acid SCHEMBL7278029 | 0.79 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7280500 | 0.79 | PDE5A (0.62) | PDE5APTGS1TBXAS1PTGS2PDE3B | |
| SCHEMBL7280806 | 0.77 | PDE5A (1.00) | PDE5APTGS1TBXAS1PTGS2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | PDE5A 3794/4885PTGS1 419/4885TBXAS1 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.